1. Market Overview of Primary Biliary Cirrhosis Drug
1.1 Primary Biliary Cirrhosis Drug Market Overview
1.1.1 Primary Biliary Cirrhosis Drug Product Scope
1.1.2 Market Status and Outlook
1.2 Primary Biliary Cirrhosis Drug Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Primary Biliary Cirrhosis Drug Historic Market Size by Regions (2015-2020)
1.4 Primary Biliary Cirrhosis Drug Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Primary Biliary Cirrhosis Drug Sales Market by Type (2015-2026)
2.1 Global Primary Biliary Cirrhosis Drug Historic Market Size by Type (2015-2020)
2.2 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Type (2021-2026)
2.3 Budesonide
2.4 FFP-104
2.5 GSK-2330672
2.6 MBX-8025
2.7 NGM-282
2.8 Others
3. Covid-19 Impact Primary Biliary Cirrhosis Drug Sales Market by Application (2015-2026)
3.1 Global Primary Biliary Cirrhosis Drug Historic Market Size by Application (2015-2020)
3.2 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Application (2021-2026)
3.3 Clinic
3.4 Hospital
3.5 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Primary Biliary Cirrhosis Drug Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Primary Biliary Cirrhosis Drug Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Primary Biliary Cirrhosis Drug Business
5.1 AlbireoPharma
5.1.1 AlbireoPharma Company Profile
5.1.2 AlbireoPharma Primary Biliary Cirrhosis Drug Product Specification
5.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 CymaBay Therapeutics Inc.
5.2.1 CymaBay Therapeutics Inc. Company Profile
5.2.2 CymaBay Therapeutics Inc. Primary Biliary Cirrhosis Drug Product Specification
5.2.3 CymaBay Therapeutics Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Dr. Falk Pharma GmbH
5.3.1 Dr. Falk Pharma GmbH Company Profile
5.3.2 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Specification
5.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 Enanta Pharmaceuticals Inc.
5.4.1 Enanta Pharmaceuticals Inc. Company Profile
5.4.2 Enanta Pharmaceuticals Inc. Primary Biliary Cirrhosis Drug Product Specification
5.4.3 Enanta Pharmaceuticals Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 GlaxoSmithKline Plc
5.5.1 GlaxoSmithKline Plc Company Profile
5.5.2 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Specification
5.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Intercept Pharmaceuticals Inc.
5.6.1 Intercept Pharmaceuticals Inc. Company Profile
5.6.2 Intercept Pharmaceuticals Inc. Primary Biliary Cirrhosis Drug Product Specification
5.6.3 Intercept Pharmaceuticals Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Johnson & Johnson
5.7.1 Johnson & Johnson Company Profile
5.7.2 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Specification
5.7.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 MediGene AG
5.8.1 MediGene AG Company Profile
5.8.2 MediGene AG Primary Biliary Cirrhosis Drug Product Specification
5.8.3 MediGene AG Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 NGM Biopharmaceuticals Inc.
5.9.1 NGM Biopharmaceuticals Inc. Company Profile
5.9.2 NGM Biopharmaceuticals Inc. Primary Biliary Cirrhosis Drug Product Specification
5.9.3 NGM Biopharmaceuticals Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Virobay Inc.
5.10.1 Virobay Inc. Company Profile
5.10.2 Virobay Inc. Primary Biliary Cirrhosis Drug Product Specification
5.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Primary Biliary Cirrhosis Drug Market Size (2015-2026)
6.2 North America Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
6.3 North America Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
6.4 North America Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Primary Biliary Cirrhosis Drug Market Size (2015-2026)
7.2 East Asia Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
7.3 East Asia Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
7.4 East Asia Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
8. Europe
8.1 Europe Primary Biliary Cirrhosis Drug Market Size (2015-2026)
8.2 Europe Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
8.3 Europe Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
8.4 Europe Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Primary Biliary Cirrhosis Drug Market Size (2015-2026)
9.2 South Asia Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
9.3 South Asia Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
9.4 South Asia Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Primary Biliary Cirrhosis Drug Market Size (2015-2026)
10.2 Southeast Asia Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
10.3 Southeast Asia Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
10.4 Southeast Asia Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Primary Biliary Cirrhosis Drug Market Size (2015-2026)
11.2 Middle East Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
11.3 Middle East Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
11.4 Middle East Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
12. Africa
12.1 Africa Primary Biliary Cirrhosis Drug Market Size (2015-2026)
12.2 Africa Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
12.3 Africa Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
12.4 Africa Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Primary Biliary Cirrhosis Drug Market Size (2015-2026)
13.2 Oceania Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
13.3 Oceania Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
13.4 Oceania Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
14. South America
14.1 South America Primary Biliary Cirrhosis Drug Market Size (2015-2026)
14.2 South America Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
14.3 South America Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
14.4 South America Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Primary Biliary Cirrhosis Drug Market Size (2015-2026)
15.2 Rest of the World Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)
15.3 Rest of the World Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
15.4 Rest of the World Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
16 Primary Biliary Cirrhosis Drug Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porters Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.